Original research: Risk factors for mortality from primary cryptococcosis in patients with HIV

Postgraduate Medicine

Volumn 121, Issue 2, 2009, Pages 107-113

  Sajadi, Mohammad M ^a   Roddy, Kristina M ^a   Chan Tack, Kirk M ^b   Forrest, Graeme N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

AIDS; Cryptococcosis; HIV; Infectious disease; Inpatient; Mortality; Outcomes; Pneumonia

Indexed keywords

AMPHOTERICIN B; BACTERIAL ANTIGEN; FLUCONAZOLE; FLUCYTOSINE;

ANGIONEUROTIC EDEMA; ARTICLE; BLOODSTREAM INFECTION; BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM INFECTION; CONCURRENT INFECTION; CRYPTOCOCCOSIS; DEMOGRAPHY; FEVER; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; LUMBAR PUNCTURE; MEDICAL RECORD REVIEW; MORTALITY; PATIENT ASSESSMENT; PNEUMONIA; RESPIRATORY FAILURE; RISK FACTOR; STEVENS JOHNSON SYNDROME; SURVIVAL; SYNCOPE; THROMBOPHLEBITIS; UNITED STATES; UREMIA; AIDS RELATED COMPLEX; CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; FEMALE; MALE; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CRYPTOCOCCOSIS; FEMALE; HUMANS; MALE; MARYLAND; MENINGITIS, CRYPTOCOCCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 64849111108     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.03.1983     Document Type: Article

References (36)

1. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis: a study in 111 cases. Ann Intern Med. 1974;80(2):176-181.
2. White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis. 1992;165(5):960-963.
3. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992;326(2):83-89.
4. Van der horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337(1):15-21.
5. Graybill JR, Sobel J, Saag MS, et al. Diagnosis and managment of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30(1):47-54.
6. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000;30(4):710-718.
7. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS. 2007;21(16):2119-2129. (Pubitemid 350287209)
8. Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4(2):e21. (Pubitemid 46354443)
9. Dromer F, Mathoulin-Pélissier S, Fontanet A, Ronin O, Dupont B, Lortholary O; French Cryptococcosis Study Group. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS. 2004;18(3):555-562.
10. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis. 2003;36(6):789-794. (Pubitemid 36337986)
11. Pukkila-Worley R, Mylonakis E. Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother. 2008;9(4):551-560.
12. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764-1767. (Pubitemid 38698379)
13. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Treatment of cryptococcosis in the setting of HIV coinfection. Expert Rev Anti Infect Ther. 2007;5(6):1019-11013 (Pubitemid 350303030)
14. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008;47(1):123-130.
15. Powderly WG. Editorial commentary: dosing amphotericin B in cryptococcal meningitis. Clin Infect Dis. 2008;47(1):131-132.
16. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46(11):1694-11670
17. Asawavichienjinda T, Sitthi-Amorn C, Tanyanont V. Serum cyrptococcal antigen: diagnostic value in the diagnosis of AIDS-related cryptococcal meningitis. J Med Assoc Thai. 1999;82(1):65-71.
18. Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis. 2000;30(6):882-892. (Pubitemid 32250325)
19. French MA, Lenzo N, John M, Mallal SA, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000;1(2):107-115.
20. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine. 2002;81(3):213-227. (Pubitemid 34507208)
21. Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis. 2002;34(2):224-233. (Pubitemid 34028357)
22. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis. 2002;35(12):e128-e133.
23. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18(12):1615-1627. (Pubitemid 39095778)
24. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38(8):1159-1166. (Pubitemid 38951265)
25. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4):399-406. (Pubitemid 40446186)
26. Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol. 2005;11(suppl 3):16-22.
27. Broom J, Woods M 2nd, Allworth A. Immune reconstitution inflammatory syndrome producing atypical presentations of cryptococcal meningitis: case report and a review of immune reconstitution-associated cryptococcal infections. Scand J Infect Dis. 2006;38(8):219-221. (Pubitemid 43307536)
28. Lipman M, Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis. 2006;19(1):20-25. (Pubitemid 43032435)
29. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57(2):167-170. (Pubitemid 43160154)
30. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr. 2007;45(5):595-596. (Pubitemid 47294935)
31. Charlier C, Dromer F, Leveque C, et al; French Cryptococcosis Study Group. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PloS One. 2008;3:e1950.
32. Meyohas MC, Roux P, Bollens D, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis. 1995;21(3):628-633.
33. Cameron M, Bartlett JA, Galiis HA, Waskiin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis. 1991;13(1):64-67.
34. Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Cryptococcus neoformans meningitis at 2 hospitals in Washington, DC: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2005;40(3):477-479. (Pubitemid 40216519)
35. Rogers FB, Shackford SR, Trevisani GT, Davis JW, Mackersie RC, Hoyt DB. Neurogenic pulmonary edema in fatal and nonfatal head injuries. J Trauma. 1995;39(5):860-866.
36. Sedý J, Zicha J, Kuneš J, Jendelová P, Syková E. Mechanisms of neurogenic pulmonary edema development. Physiol Res. 2008;57(4):499-506.